The company plans to launch 14 products in Brazil, targeting a potential market of USD 2 billion, expanding access to high-complexity treatments in key therapeutic areas, expecting to generate over USD 130 million in sales within the next 4 years. Through strategic...
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks CStone’s third major global commercialization partnership for...
GUANGZHOU, China and San Jose, Costa Rica – SteinCares, a leading specialty healthcare company in Latin America, and Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced an expansion...
Haemoctin® becomes the company’s first biological product in the plasma-derived segment, offering a cost-effective alternative for the treatment of hemophilia in the region. This partnership reinforces SteinCares’ leadership in expanding access to...
The acquisition strengthens SteinCares’ leadership and operations in the country and is expected to contribute to the subsidiary’s growth. The deal includes the marketing and distribution license for a treatment for severe pain. San Jose, Costa Rica,...
